

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2022/261467 A9

(43) International Publication Date
15 December 2022 (15.12.2022)

WIPO | PCT

(51) International Patent Classification:

A61K 51/00 (2006.01) A61K 51/04 (2006.01)
A61K 51/02 (2006.01) C07D 257/00 (2006.01)

(21) International Application Number:

PCT/US2022/033058

(22) International Filing Date:

10 June 2022 (10.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/209,736 11 June 2021 (11.06.2021) US

(71) Applicant: FUSION PHARMACEUTICALS INC.

[CA/CA]; 270 Longwood Road South, Hamilton, Ontario
L8P 0A6 (CA).

(72) Inventors: BURAK, Eric Steven; 40 James Street,

Cambridge, Ontario N1S 1C5 (CA). METCALF, Julie;
8 Pointview Ave, Brantford, Ontario N3R1B4 (CA).
GRINSHEIN, Natalie; 3630 212th Pl. SE, Bothell, WA
98021 (US). HU, Meiduo; 10584 Bathurst Street, Maple,
Ontario L94 4Y4 (CA). VALLIANT, John Fitzmaurice;
15 Holkham Avenue, Ancaster, Ontario L9K 1N8 (CA).

(74) Agent: BIEKER, Kristina et al.; Goodwin Procter LLP,

100 Northern Avenue, IP DOCKETING DEPT./7TH FL,
Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the revised international search report:

04 May 2023 (04.05.2023)

(15) Information about Correction:

see Notice of 04 May 2023 (04.05.2023)

(54) Title: RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY




FIG. 8B

(57) Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.

WO 2022/261467 A9